Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

GH Guardant Health Inc.

Trading 02-06 13:24:54 EST

100.55

+2.19

+2.23%

High102.69	Low97.52	Vol888.65K
Open100.39	D1 Closing98.36	Amplitude5.26%
Mkt Cap13.01B	Tradable Cap12.47B	Total Shares129.37M
T/O89.27M	T/O Rate0.72%	Tradable Shares124.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"GH","market":"US","secType":"STK","nameCN":"Guardant Health Inc.","latestPrice":100.55,"timestamp":1770402292985,"preClose":98.36,"halted":0,"volume":888647,"delay":0,"changeRate":0.02226514843432287,"floatShares":124000000,"shares":129374422,"eps":-3.212374,"marketStatus":"Trading","change":2.19,"latestTime":"02-06 13:24:54 EST","open":100.385,"high":102.69,"low":97.52,"amount":89270633.9496,"amplitude":0.052562,"askPrice":100.68,"askSize":193,"bidPrice":100.34,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-3.212374,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770411600000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1538625600000,"exchange":"NASDAQ","adjPreClose":98.36,"preHourTrading":{"tag":"盘前","latestPrice":101.27,"preClose":98.36,"latestTime":"09:28 EST","volume":828,"amount":83168.69184,"timestamp":1770388080036,"change":2.91,"changeRate":0.029585,"amplitude":0.023078},"postHourTrading":{"tag":"盘后","latestPrice":100.48,"preClose":98.36,"latestTime":"19:54 EST","volume":26303,"amount":2587550.5662,"timestamp":1770339241008,"change":2.12,"changeRate":0.021553,"amplitude":0.021553},"volumeRatio":0.506699,"impliedVol":0.7576,"impliedVolPercentile":0.9084},"requestUrl":"/m/hq/s/GH","defaultTab":"news","newsList":[{"id":"2608001488","title":"Guardant Health nimmt an der Barclays Global Healthcare Conference in Miami Beach teil","url":"https://stock-news.laohu8.com/highlight/detail?id=2608001488","media":"Reuters","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608001488?lang=en_us&edition=fundamental","pubTime":"2026-02-04 05:06","pubTimestamp":1770152814,"startTime":"0","endTime":"0","summary":"Guardant Health Inc. wird am Mittwoch, den 11. Mrz, um 13:00 Uhr Eastern Time an einem Fireside-Chat auf der Barclays 28th Annual Global Healthcare Conference in Miami Beach, FL teilnehmen.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire  on February 03, 2026, and is solely responsible for the information contained therein.","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260203:nNDL5rNQbW:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4196","BK4535","GH","BK4588","BK4551"],"gpt_icon":0},{"id":"2608867556","title":"Guardant reports publication of circulating tumor DNA for MRD detection study","url":"https://stock-news.laohu8.com/highlight/detail?id=2608867556","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608867556?lang=en_us&edition=fundamental","pubTime":"2026-02-02 22:20","pubTimestamp":1770042034,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced publication of the largest study to date evaluating circulating tumor DNA for MRD detection in patients with resecte...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-reports-publication-of-circulating-tumor-dna-for-mrd-detection-study-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-reports-publication-of-circulating-tumor-dna-for-mrd-detection-study-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4196","GH","BK4588","DNA","BK4139","BK4121","BK4109","BK4551","BK4585","BK4535"],"gpt_icon":0},{"id":"2608861677","title":"Guardant Reveal Blood Test Improves Recurrence Prediction in Stage III Colon Cancer Patients","url":"https://stock-news.laohu8.com/highlight/detail?id=2608861677","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2608861677?lang=en_us&edition=fundamental","pubTime":"2026-02-02 21:05","pubTimestamp":1770037519,"startTime":"0","endTime":"0","summary":"Guardant Health Inc. has announced the publication of results from the largest study to date evaluating circulating tumor DNA  for molecular residual disease  detection in patients with resected stage III colon cancer. The study, conducted in collaboration with Mayo Clinic and the Alliance for Clinical Trials in Oncology, was published in the Journal of Clinical Oncology. Findings indicate that the Guardant Reveal blood test more precisely identifies the risk of cancer recurrence and overall survival compared to standard staging methods. The data support the routine use of ctDNA testing in the management of stage III colon cancer patients, providing clinicians with actionable insights for post-surgical treatment decisions.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as finan","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260202:nNDLbjsR0l:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4551","BK4588","BK4535","BK4585","GH"],"gpt_icon":0},{"id":"2607040574","title":"UBS Adjusts Price Target on Guardant Health to $175 From $110, Maintains Buy Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2607040574","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607040574?lang=en_us&edition=fundamental","pubTime":"2026-01-31 00:02","pubTimestamp":1769788964,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) has an average rating of overweight and mean price target of $126.59, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from maj","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4535","GH","BK4196","BK4551","BK4585","BK4588"],"gpt_icon":0},{"id":"2607561200","title":"Guardant Health Inc. to Report Fourth Quarter and Full Year 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2607561200","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607561200?lang=en_us&edition=fundamental","pubTime":"2026-01-30 05:05","pubTimestamp":1769720756,"startTime":"0","endTime":"0","summary":"Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via Business Wire  on January 29, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260129:nNDLbqxgyp:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4535","BK4585","BK4588","BK4551","BK4196","GH"],"gpt_icon":0},{"id":"2607031397","title":"Psychedelic: Analyst raises Compass, Definium, GH Research price targets","url":"https://stock-news.laohu8.com/highlight/detail?id=2607031397","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607031397?lang=en_us&edition=fundamental","pubTime":"2026-01-29 23:30","pubTimestamp":1769700642,"startTime":"0","endTime":"0","summary":"In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on price target raises, advisory boa...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/psychedelic-analyst-raises-compass-definium-gh-research-price-targets-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/psychedelic-analyst-raises-compass-definium-gh-research-price-targets-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GH"],"gpt_icon":0},{"id":"2606242641","title":"Guardant Health Is Maintained at Buy by Guggenheim","url":"https://stock-news.laohu8.com/highlight/detail?id=2606242641","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2606242641?lang=en_us&edition=fundamental","pubTime":"2026-01-27 00:45","pubTimestamp":1769445900,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GH/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 26, 2026 11:45 ET (16:45 GMT)","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4196","BK4535","BK4551","BK4585","BK4588","GH"],"gpt_icon":0},{"id":"2605238494","title":"FDA Approves New Colorectal Cancer Use For Guardant360 Might Change The Case For Investing In Guardant Health (GH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2605238494","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605238494?lang=en_us&edition=fundamental","pubTime":"2026-01-24 10:39","pubTimestamp":1769222376,"startTime":"0","endTime":"0","summary":"Earlier this week, Guardant Health received FDA approval for its Guardant360 CDx liquid biopsy as a companion diagnostic to identify BRAF V600E-mutant metastatic colorectal cancer patients eligible for treatment with BRAFTOVI (encorafenib) plus cetuximab and chemotherapy.\nThis marks the test’s first approval in colorectal cancer and its 25th companion diagnostic indication overall, underscoring the expanding role of non-invasive genomic profiling in tailoring treatment when tissue samples...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6032000-choice2-main-header/1585186864566"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/fda-approves-new-colorectal-cancer-use-for-guardant360-might","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/healthcare/nasdaq-gh/guardant-health/news/fda-approves-new-colorectal-cancer-use-for-guardant360-might","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4196","BK4585","BK4535","GH","BK4551","BK4588"],"gpt_icon":0},{"id":"2605540021","title":"Analysts Are Bullish on These Healthcare Stocks: Vaxcyte (PCVX), Guardant Health (GH)","url":"https://stock-news.laohu8.com/highlight/detail?id=2605540021","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605540021?lang=en_us&edition=fundamental","pubTime":"2026-01-24 04:00","pubTimestamp":1769198449,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Vaxcyte (PCVX – Research Report) and Guardant Health...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-vaxcyte-pcvx-guardant-health-gh-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-are-bullish-on-these-healthcare-stocks-vaxcyte-pcvx-guardant-health-gh-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE0009354923.USD","XBI","LU0029874061.USD","LU0128526141.USD","BK4139","GH","BK4196","BK4588","BK4112","BK4581","LABU","BK4585","BK4551","LU0053671581.USD","PCVX","BK4535","BK4137"],"gpt_icon":0},{"id":"2605213400","title":"Leerink sees Court ruling as small win for Guardant, no change to patent risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2605213400","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605213400?lang=en_us&edition=fundamental","pubTime":"2026-01-24 03:50","pubTimestamp":1769197824,"startTime":"0","endTime":"0","summary":"Leerink says the Court decision is an incremental positive in Guardant Health’s (GH) litigation against the University of Washington and TwinStrand...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/leerink-sees-court-ruling-as-small-win-for-guardant-no-change-to-patent-risk-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/leerink-sees-court-ruling-as-small-win-for-guardant-no-change-to-patent-risk-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4551","BK4535","BK4585","BK4196","GH","BK4588"],"gpt_icon":0},{"id":"2605400150","title":"GH Research price target raised to $40 from $33 at RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2605400150","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605400150?lang=en_us&edition=fundamental","pubTime":"2026-01-24 03:25","pubTimestamp":1769196314,"startTime":"0","endTime":"0","summary":"RBC Capital raised the firm’s price target on GH Research (GHRS) to $40 from $33 and keeps an Outperform rating on the shares. Following the firm’s...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/gh-research-price-target-raised-to-40-from-33-at-rbc-capital-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/gh-research-price-target-raised-to-40-from-33-at-rbc-capital-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GH"],"gpt_icon":0},{"id":"2605401863","title":"GH Research Is Maintained at Outperform by RBC Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2605401863","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605401863?lang=en_us&edition=fundamental","pubTime":"2026-01-23 23:29","pubTimestamp":1769182140,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/GHRS/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  January 23, 2026 10:29 ET (15:29 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH"],"gpt_icon":0},{"id":"2605705984","title":"RBC Raises Price Target on GH Research to $40 From $33, Keeps Outperform, Speculative Risk","url":"https://stock-news.laohu8.com/highlight/detail?id=2605705984","media":"MT Newswires Live","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605705984?lang=en_us&edition=fundamental","pubTime":"2026-01-23 20:54","pubTimestamp":1769172841,"startTime":"0","endTime":"0","summary":"GH Research (GHRS) has an average rating of buy and mean price target of $33.50, according to analysts polled by FactSet.(MT Newswires covers equity, commodity and economic research from major banks a","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate","earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["GH"],"gpt_icon":0},{"id":"2605470259","title":"RBC Capital Remains a Buy on GH Research (GHRS)","url":"https://stock-news.laohu8.com/highlight/detail?id=2605470259","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605470259?lang=en_us&edition=fundamental","pubTime":"2026-01-23 20:51","pubTimestamp":1769172693,"startTime":"0","endTime":"0","summary":"RBC Capital analyst Brian Abrahams maintained a Buy rating on GH Research today and set a price target of $40.00. According to TipRanks, Abrahams i...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-gh-research-ghrs-blurbs?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/rbc-capital-remains-a-buy-on-gh-research-ghrs-blurbs?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GH","BK4588","LU0128525929.USD","BK4196","BK4535","BK4539","LU0310800379.SGD","LU0708994859.HKD","LU1267930573.SGD","GHRS","BK4551","LU0029864427.USD","BK4207","BK4007","BK4585"],"gpt_icon":0},{"id":"2605443918","title":"Guardant Health Chief People Officer Terilyn J. Monroe Reports Sale of Common Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2605443918","media":"Reuters","labels":["shareholding","insiderTrades","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605443918?lang=en_us&edition=fundamental","pubTime":"2026-01-23 06:45","pubTimestamp":1769121956,"startTime":"0","endTime":"0","summary":"Terilyn J. Monroe, Chief People Officer of Guardant Health Inc., reported a disposal of common shares of Guardant Health Inc. The full filing can be accessed through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission , on January 22, 2026, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL6NlLJC:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":"Guardant Health Chief People Officer Terilyn J. Monroe Reports Sale of Common Shares","news_tag":"shareholding,insiderTrades,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4196","GH","BK4588","BK4551","BK4535"],"gpt_icon":0},{"id":"2605499208","title":"FDA Approves Guardant360 CDx as Companion Diagnostic for BRAFTOVI Combination in BRAF V600E-Mutant Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2605499208","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605499208?lang=en_us&edition=fundamental","pubTime":"2026-01-22 21:05","pubTimestamp":1769087118,"startTime":"0","endTime":"0","summary":"FDA Approves Guardant360 CDx as Companion Diagnostic for BRAFTOVI Combination in BRAF V600E-Mutant Metastatic Colorectal Cancer. Guardant Health Inc. has received U.S. Food and Drug Administration  approval for its Guardant360 CDx test as a companion diagnostic to identify patients with BRAF V600E-mutant metastatic colorectal cancer  who may benefit from treatment with BRAFTOVI  in combination with cetuximab and chemotherapy. This marks the first FDA-approved companion diagnostic indication for Guardant360 CDx in colorectal cancer and expands its role in guiding targeted therapy across solid tumors. The approval is supported by data from Pfizer's Phase 3 BREAKWATER trial, which demonstrated improved outcomes in patients treated with encorafenib-based regimens. The Guardant360 CDx test enables non-invasive genomic testing through a blood draw, facilitating timely treatment decisions for patients when tumor tissue is unavailable or insufficient.Disclaimer: This news brief was created by ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nNDL5bjKZZ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1894683264.USD","LU0122379950.USD","IE000M9KFDE8.USD","IE00B19Z3B42.SGD","LU0868494617.USD","BK4535","BK4585","BK4568","LU0456855351.SGD","BK4550","IE00BLSP4239.USD","SG9999002224.SGD","BK4592","LU1883839398.USD","BK4196","LU1023059063.AUD","LU1066051498.USD","LU1894683348.USD","BK4534","LU0321505439.SGD","IE00BLSP4452.SGD","LU0985481810.HKD","BK4551","LU0289739699.SGD","BK4533","LU0321505868.SGD","LU0234572021.USD","SG9999001176.USD","SG9999001176.SGD","GH","LU0058720904.USD","BK4007","BK4581","LU0170899867.USD","LU1057294990.SGD","SG9999002232.USD","LU0306806265.USD","IE0002270589.USD","BK4599","SG9999013999.USD","BK4588","IE00BBT3K403.USD","LU1066053197.SGD","LU0225771236.USD","SG9999011175.SGD","LU0306807586.USD","SGXZ57979304.SGD","IE00B19Z3581.USD","SG9999003800.SGD","LU0225284248.USD"],"gpt_icon":0},{"id":"2605849921","title":"Guardant Health Receives FDA Approval for Guardant360® Cdx as Companion Diagnostic for Braftovi® (Encorafenib) Combination in Patients With Braf V600e-Mutant Metastatic Colorectal Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2605849921","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2605849921?lang=en_us&edition=fundamental","pubTime":"2026-01-22 21:05","pubTimestamp":1769087100,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260122:nTUA8QY4BF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["GH","BK4585","BK4588","BK4551","BK4535","BK4196"],"gpt_icon":0},{"id":"2604538271","title":"Guardant Health announces multi-year strategic agreement with Merck","url":"https://stock-news.laohu8.com/highlight/detail?id=2604538271","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604538271?lang=en_us&edition=fundamental","pubTime":"2026-01-20 03:50","pubTimestamp":1768852218,"startTime":"0","endTime":"0","summary":"Guardant Health (GH) announced a multi-year collaboration with Merck (MRK), known as MSD outside the United States and Canada, to support the devel...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/guardant-health-announces-multi-year-strategic-agreement-with-merck-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/guardant-health-announces-multi-year-strategic-agreement-with-merck-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU1430594728.SGD","LU0980610538.SGD","LU0289739699.SGD","SG9999013999.USD","SG9999014567.USD","SG9999002224.SGD","BK4196","SG9999015341.SGD","LU1037948897.HKD","IE00BFTCPJ56.SGD","SG9999001176.SGD","IE00BN8TJ469.HKD","LU1116320901.HKD","IE00BJT1NW94.SGD","BK4516","LU0965508806.USD","LU2125154935.USD","LU1989772923.USD","SG9999014542.SGD","LU0203347892.USD","LU1934455863.HKD","LU2361045086.USD","LU0985320562.USD","IE000M9KFDE8.USD","LU2468319806.SGD","LU0130517989.USD","IE00BLSP4239.USD","SGXZ57979304.SGD","LU1069347547.HKD","LU0203345920.USD","LU1585245621.USD","BK4533","LU0648001328.SGD","LU1983299246.USD","SG9999002232.USD","LU1116320737.USD","BK4550","LU0965509010.AUD","LU0965509283.SGD","IE00B1BXHZ80.USD","BK4559","LU1941712348.USD","LU0234572021.USD","LU1061106388.HKD","LU0058720904.USD","IE00BBT3K403.USD","LU2106854487.HKD","LU1571399168.USD","BK4588","LU1934455194.USD","BK4535","GH","BK4007","LU0208291251.USD","LU0965509101.SGD","LU1023059063.AUD","BK4585","LU1699723380.USD","LU2023250504.SGD","LU1037948541.HKD","LU0006306889.USD","LU1057294990.SGD","MRK","LU1974910355.USD","LU2361044949.HKD","LU0265550359.USD","LU1066051498.USD","IE00B4R5TH58.HKD","SG9999001440.SGD","IE0009355771.USD","LU0477156953.USD","LU1093756168.USD","LU1989771016.USD","LU0070302665.USD","LU1989772840.SGD","LU0320765646.SGD","LU0238689110.USD","LU2023250843.SGD","LU1066051811.HKD","LU1093756325.SGD","LU0106261372.USD","SG9999014559.SGD","SG9999015358.SGD","BK4551","LU0861579265.USD","IE00B2B36J28.USD","LU1934455277.USD","LU1941712264.USD","LU0130102774.USD","LU2324357040.USD","BK4534","IE00BSNM7G36.USD","LU0211331839.USD","IE00BLSP4452.SGD","LU2461242641.AUD","LU0266013472.USD","LU1066051225.USD","LU0122379950.USD","LU2125154778.USD","LU1929549753.HKD","IE00BJJMRZ35.SGD","LU0098860793.USD","LU1035773651.USD","LU2089984988.USD","LU1201861249.SGD","LU1917777945.USD","LU1066053197.SGD","LU1291159041.SGD","LU2112291526.USD","IE0002141913.USD","LU2360032135.SGD","LU0265550946.USD","SG9999014575.USD","LU2361044865.SGD","LU1162221912.USD","SG9999001176.USD","LU0320765489.SGD"],"gpt_icon":0},{"id":"2604137605","title":"Guardant Health projects 2025 revenue to reach $981 million","url":"https://stock-news.laohu8.com/highlight/detail?id=2604137605","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604137605?lang=en_us&edition=fundamental","pubTime":"2026-01-20 01:17","pubTimestamp":1768843032,"startTime":"0","endTime":"0","summary":"Guardant Health Inc. reported strong revenue growth in 2025, with fourth quarter revenue reaching $280 million and full-year revenue totaling $981 million, representing a 39% year-over-year increase for the quarter and a 33% year-over-year increase for the full year. The company highlighted that its expanded product offering and operational excellence have accelerated revenue growth, with total revenue rising from $374 million in 2021 to an estimated $981 million in 2025. Significant milestones were delivered across the continuum of cancer care during the year, contributing to the positive business performance.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Guardant Health Inc. published the original content used to generate this news ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nNDL1JyNTw:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["GH","BK4551","BK4588","BK4196","BK4535","BK4585"],"gpt_icon":0},{"id":"2604131362","title":"BRIEF-Guardant Health Announces Multi-Year Strategic Collaboration Agreement With Merck","url":"https://stock-news.laohu8.com/highlight/detail?id=2604131362","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2604131362?lang=en_us&edition=fundamental","pubTime":"2026-01-19 22:32","pubTimestamp":1768833176,"startTime":"0","endTime":"0","summary":"BRIEF-Guardant Health Announces Multi-Year Strategic Collaboration Agreement With Merck Jan 19 (Reuters) - Guardant Health Inc GH.O:GUARDANT HEALTH ANNOUNCES MULTI-YEAR STRATEGIC COLLABORATION AGREEME","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260119:nTUABFYVDR:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1057294990.SGD","IE00B4R5TH58.HKD","LU1934455863.HKD","LU1430594728.SGD","LU0477156953.USD","LU0238689110.USD","IE000M9KFDE8.USD","LU0122379950.USD","LU1093756168.USD","LU0861579265.USD","IE00BFTCPJ56.SGD","LU0965508806.USD","MRK","BK4196","BK4535","IE00B2B36J28.USD","LU0211331839.USD","LU0980610538.SGD","LU1061106388.HKD","LU1934455277.USD","SGXZ57979304.SGD","BK4516","LU1941712264.USD","LU0203347892.USD","LU2125154778.USD","SG9999013999.USD","LU0106261372.USD","LU1116320737.USD","LU0130102774.USD","LU0265550946.USD","LU1571399168.USD","LU2468319806.SGD","LU2023250504.SGD","LU2361044949.HKD","LU0648001328.SGD","BK4550","LU1066051225.USD","LU2089984988.USD","SG9999015341.SGD","SG9999015358.SGD","LU0208291251.USD","LU2361044865.SGD","LU0320765646.SGD","LU0289739699.SGD","LU1929549753.HKD","LU1989772923.USD","LU2360032135.SGD","BK4533","IE00BBT3K403.USD","LU0070302665.USD","LU2361045086.USD","LU2125154935.USD","LU1037948897.HKD","LU2461242641.AUD","SG9999001176.SGD","SG9999014575.USD","LU2106854487.HKD","LU0234572021.USD","BK4551","IE0002141913.USD","LU1093756325.SGD","LU1585245621.USD","LU1974910355.USD","SG9999001440.SGD","SG9999014567.USD","LU0266013472.USD","GH","LU2023250843.SGD","SG9999014559.SGD","LU0965509010.AUD","LU1162221912.USD","SG9999002232.USD","BK4585","LU1069347547.HKD","LU1035773651.USD","LU1291159041.SGD","LU1989772840.SGD","LU1066053197.SGD","LU0098860793.USD","LU2112291526.USD","LU0006306889.USD","BK4007","LU1989771016.USD","LU2324357040.USD","BK4588","LU0985320562.USD","SG9999002224.SGD","SG9999014542.SGD","LU0058720904.USD","LU0320765489.SGD","IE00BSNM7G36.USD","LU1116320901.HKD","IE00BLSP4239.USD","LU0130517989.USD","LU1066051498.USD","LU1023059063.AUD","LU1066051811.HKD","LU0203345920.USD","IE00BLSP4452.SGD","LU1917777945.USD","LU1983299246.USD","LU0965509101.SGD","LU1941712348.USD","BK4534","IE0009355771.USD","BK4559","LU1699723380.USD","LU1934455194.USD","IE00BJJMRZ35.SGD","LU1201861249.SGD","SG9999001176.USD","LU0265550359.USD","LU1037948541.HKD","IE00BJT1NW94.SGD","LU0965509283.SGD","IE00B1BXHZ80.USD","IE00BN8TJ469.HKD"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.guardanthealth.com","stockEarnings":[{"period":"1week","weight":-0.1097},{"period":"1month","weight":-0.1244},{"period":"3month","weight":0.017},{"period":"6month","weight":0.8138},{"period":"1year","weight":1.0666},{"period":"ytd","weight":-0.037}],"compareEarnings":[{"period":"1week","weight":-0.0237},{"period":"1month","weight":-0.0205},{"period":"3month","weight":0.0099},{"period":"6month","weight":0.0635},{"period":"1year","weight":0.1215},{"period":"ytd","weight":-0.0063}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.625,"avgChangeRate":0.071093},{"month":2,"riseRate":0.25,"avgChangeRate":0.03904},{"month":3,"riseRate":0.571429,"avgChangeRate":-0.023739},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.017651},{"month":5,"riseRate":0.571429,"avgChangeRate":0.065461},{"month":6,"riseRate":0.714286,"avgChangeRate":0.081894},{"month":7,"riseRate":0.714286,"avgChangeRate":0.051469},{"month":8,"riseRate":0.571429,"avgChangeRate":0.08346},{"month":9,"riseRate":0.285714,"avgChangeRate":-0.065825},{"month":10,"riseRate":0.285714,"avgChangeRate":0.030366},{"month":11,"riseRate":0.75,"avgChangeRate":0.130427},{"month":12,"riseRate":0.5,"avgChangeRate":-0.066498}],"exchange":"NASDAQ","name":"Guardant Health Inc.","nameEN":"Guardant Health Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Guardant Health Inc.(GH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Guardant Health Inc.,GH,Guardant Health Inc.股票,Guardant Health Inc.股票老虎,Guardant Health Inc.股票老虎国际,Guardant Health Inc.行情,Guardant Health Inc.股票行情,Guardant Health Inc.股价,Guardant Health Inc.股市,Guardant Health Inc.股票价格,Guardant Health Inc.股票交易,Guardant Health Inc.股票购买,Guardant Health Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Guardant Health Inc.(GH),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Guardant Health Inc.(GH) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction